Press releases

• November 30, 2022 - Regulatory press releaseNumber of shares and votes in BioArctic AB (publ) as of November 30, 2022
• November 30, 2022 - Regulatory press releaseFull results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s disease published in the New England Journal of Medicine
• November 30, 2022 - Regulatory press releaseBioArctic’s partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer’s disease at CTAD conference

Archive

Calendar

• February 3, 2023 08:00 CETFull year report January – December 2022
• April 27, 2023 08:00 CETInterim report January – March 2023
• June 1, 2023Annual General Meeting 2023
• July 12, 2023 08:00 CETHalf-Year report January – July 2023
• November 8, 2023 08:00 CETInterim report January – September 2023

Read more

Interim report Q3 2022

BioArctic AB published the company’s third quarter report for July – September 2022 on Thursday, October 20, 2022, at 08:00 a.m. CET.

• Report
• Presentation
• Webcast

Read the report

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more